PMC:7534206 / 11051-11996 JSONTXT

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T32","span":{"begin":193,"end":200},"obj":"Body_part"},{"id":"T33","span":{"begin":764,"end":770},"obj":"Body_part"},{"id":"T34","span":{"begin":854,"end":859},"obj":"Body_part"}],"attributes":[{"id":"A32","pred":"uberon_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/UBERON_0000055"},{"id":"A33","pred":"uberon_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/UBERON_0000055"},{"id":"A34","pred":"uberon_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T138","span":{"begin":139,"end":147},"obj":"Disease"},{"id":"T139","span":{"begin":717,"end":725},"obj":"Disease"},{"id":"T140","span":{"begin":727,"end":751},"obj":"Disease"},{"id":"T141","span":{"begin":847,"end":853},"obj":"Disease"},{"id":"T143","span":{"begin":883,"end":902},"obj":"Disease"}],"attributes":[{"id":"A138","pred":"mondo_id","subj":"T138","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A139","pred":"mondo_id","subj":"T139","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A140","pred":"mondo_id","subj":"T140","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A141","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A142","pred":"mondo_id","subj":"T141","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A143","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0002679"},{"id":"A144","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0005098"},{"id":"A145","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0011057"},{"id":"A146","pred":"mondo_id","subj":"T143","obj":"http://purl.obolibrary.org/obo/MONDO_0020671"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T110","span":{"begin":173,"end":177},"obj":"http://purl.obolibrary.org/obo/UBERON_0003101"},{"id":"T111","span":{"begin":173,"end":177},"obj":"http://www.ebi.ac.uk/efo/EFO_0000970"},{"id":"T112","span":{"begin":193,"end":200},"obj":"http://purl.obolibrary.org/obo/UBERON_0000055"},{"id":"T113","span":{"begin":345,"end":347},"obj":"http://purl.obolibrary.org/obo/CLO_0050507"},{"id":"T114","span":{"begin":362,"end":365},"obj":"http://purl.obolibrary.org/obo/CLO_0001527"},{"id":"T115","span":{"begin":389,"end":391},"obj":"http://purl.obolibrary.org/obo/CLO_0001407"},{"id":"T116","span":{"begin":470,"end":473},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T117","span":{"begin":574,"end":576},"obj":"http://purl.obolibrary.org/obo/CLO_0001000"},{"id":"T118","span":{"begin":582,"end":584},"obj":"http://purl.obolibrary.org/obo/CLO_0050509"},{"id":"T119","span":{"begin":585,"end":589},"obj":"http://purl.obolibrary.org/obo/CLO_0001445"},{"id":"T120","span":{"begin":764,"end":770},"obj":"http://purl.obolibrary.org/obo/UBERON_0000055"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T25","span":{"begin":201,"end":203},"obj":"Chemical"},{"id":"T26","span":{"begin":355,"end":357},"obj":"Chemical"},{"id":"T27","span":{"begin":394,"end":396},"obj":"Chemical"},{"id":"T28","span":{"begin":401,"end":403},"obj":"Chemical"},{"id":"T29","span":{"begin":404,"end":406},"obj":"Chemical"},{"id":"T30","span":{"begin":445,"end":447},"obj":"Chemical"},{"id":"T31","span":{"begin":448,"end":450},"obj":"Chemical"},{"id":"T32","span":{"begin":451,"end":453},"obj":"Chemical"},{"id":"T33","span":{"begin":490,"end":492},"obj":"Chemical"},{"id":"T34","span":{"begin":493,"end":495},"obj":"Chemical"},{"id":"T35","span":{"begin":496,"end":498},"obj":"Chemical"},{"id":"T36","span":{"begin":782,"end":784},"obj":"Chemical"}],"attributes":[{"id":"A25","pred":"chebi_id","subj":"T25","obj":"http://purl.obolibrary.org/obo/CHEBI_73614"},{"id":"A26","pred":"chebi_id","subj":"T26","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A27","pred":"chebi_id","subj":"T27","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A28","pred":"chebi_id","subj":"T28","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A29","pred":"chebi_id","subj":"T29","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A30","pred":"chebi_id","subj":"T30","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A31","pred":"chebi_id","subj":"T31","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A32","pred":"chebi_id","subj":"T32","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A33","pred":"chebi_id","subj":"T33","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A34","pred":"chebi_id","subj":"T34","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A35","pred":"chebi_id","subj":"T35","obj":"http://purl.obolibrary.org/obo/CHEBI_33696"},{"id":"A36","pred":"chebi_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/CHEBI_73614"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T59","span":{"begin":847,"end":853},"obj":"Phenotype"}],"attributes":[{"id":"A59","pred":"hp_id","subj":"T59","obj":"http://purl.obolibrary.org/obo/HP_0001297"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}

{"project":"LitCovid-sentences","denotations":[{"id":"T141","span":{"begin":0,"end":8},"obj":"Sentence"},{"id":"T142","span":{"begin":9,"end":147},"obj":"Sentence"},{"id":"T143","span":{"begin":148,"end":272},"obj":"Sentence"},{"id":"T144","span":{"begin":273,"end":317},"obj":"Sentence"},{"id":"T145","span":{"begin":318,"end":367},"obj":"Sentence"},{"id":"T146","span":{"begin":368,"end":412},"obj":"Sentence"},{"id":"T147","span":{"begin":413,"end":457},"obj":"Sentence"},{"id":"T148","span":{"begin":458,"end":503},"obj":"Sentence"},{"id":"T149","span":{"begin":504,"end":554},"obj":"Sentence"},{"id":"T150","span":{"begin":555,"end":589},"obj":"Sentence"},{"id":"T151","span":{"begin":590,"end":650},"obj":"Sentence"},{"id":"T152","span":{"begin":651,"end":716},"obj":"Sentence"},{"id":"T153","span":{"begin":717,"end":757},"obj":"Sentence"},{"id":"T154","span":{"begin":758,"end":817},"obj":"Sentence"},{"id":"T155","span":{"begin":818,"end":945},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}

{"project":"LitCovid-PubTator","denotations":[{"id":"294","span":{"begin":155,"end":163},"obj":"Species"},{"id":"295","span":{"begin":263,"end":272},"obj":"Disease"},{"id":"300","span":{"begin":26,"end":33},"obj":"Species"},{"id":"301","span":{"begin":103,"end":111},"obj":"Species"},{"id":"302","span":{"begin":89,"end":98},"obj":"Disease"},{"id":"303","span":{"begin":139,"end":147},"obj":"Disease"},{"id":"309","span":{"begin":909,"end":917},"obj":"Species"},{"id":"310","span":{"begin":727,"end":751},"obj":"Disease"},{"id":"311","span":{"begin":764,"end":780},"obj":"Disease"},{"id":"312","span":{"begin":847,"end":853},"obj":"Disease"},{"id":"313","span":{"begin":867,"end":902},"obj":"Disease"}],"attributes":[{"id":"A294","pred":"tao:has_database_id","subj":"294","obj":"Tax:9606"},{"id":"A295","pred":"tao:has_database_id","subj":"295","obj":"MESH:D003643"},{"id":"A300","pred":"tao:has_database_id","subj":"300","obj":"Tax:9606"},{"id":"A301","pred":"tao:has_database_id","subj":"301","obj":"Tax:9606"},{"id":"A302","pred":"tao:has_database_id","subj":"302","obj":"MESH:D003643"},{"id":"A303","pred":"tao:has_database_id","subj":"303","obj":"MESH:C000657245"},{"id":"A309","pred":"tao:has_database_id","subj":"309","obj":"Tax:9606"},{"id":"A310","pred":"tao:has_database_id","subj":"310","obj":"MESH:C000657245"},{"id":"A312","pred":"tao:has_database_id","subj":"312","obj":"MESH:D020521"},{"id":"A313","pred":"tao:has_database_id","subj":"313","obj":"MESH:D002544"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}

{"project":"2_test","denotations":[{"id":"32501751-32343504-53715177","span":{"begin":470,"end":471},"obj":"32343504"},{"id":"T89337","span":{"begin":470,"end":471},"obj":"32343504"}],"text":"Table 3. Pooled analysis: patient characteristics, treatment details, complications, and mortality for patients with LVO in the setting of COVID-19\nNo. of patients Mean age Male NIHSS Involved vessels MT treatment Solumbra No. of attempts TICI 2b/3 Complications Mortality\nWang et al.5 5 52.8 4 22.8 2.2 5 4 2.8 3 0 3\nEscalard et al.7 10 59.5 8 22 1.5 10 NA 3.5 9 4 6\nValderrama et al.8 1 52 1 NA 3 1 NA NA 0 0 0\nAvula et al.9 3 78.7 1 26 1.5 0 NA NA NA 0 3\nOxley et al.4 5 40.4 4 16.8 1 4 NA NA NA 0 0a\nCurrent series 15 64.6 8 15.1 1.4 15 13 1.4 15 2 5\nTotal n – – 26 – – 35 17 – 27 6 17\nTotal N 39.0 39 39.0 38.0 39.0 39.0 20.0 30.0 35.0 39.0 37.0\nPercentage/mean – 59.4 66.7 19.0 1.5 89.7 85.0 2.3 77.1 15.4 45.9\nCOVID-19: coronavirus disease 2019; LVO: Large Vessel Occlusion; MT: mechanical thrombectomy; NIHSS: National Institute of Health Stroke Scale; TICI: thrombolysis in cerebral infarction. aTwo patients were still in the hospital."}